The effect of antithrombotic treatment on the fecal immunochemical test for colorectal cancer screening: a nationwide cross-sectional study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The effect of antithrombotic treatment on the fecal immunochemical test for colorectal cancer screening : a nationwide cross-sectional study. / Rasmussen, Simon Ladefoged; Torp-Pedersen, Christian; Gotschalck, Kåre Andersson; Thorlacius-Ussing, Ole.
I: Endoscopy, Bind 55, Nr. 5, 2022, s. 444-455.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The effect of antithrombotic treatment on the fecal immunochemical test for colorectal cancer screening
T2 - a nationwide cross-sectional study
AU - Rasmussen, Simon Ladefoged
AU - Torp-Pedersen, Christian
AU - Gotschalck, Kåre Andersson
AU - Thorlacius-Ussing, Ole
N1 - Publisher Copyright: © 2023. Thieme. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background Screening for colorectal cancer (CRC) using the fecal immunochemical test (FIT) has been widely adopted. The use of antithrombotic treatment is increasing in the Western world. This study aimed to assess the effects of antithrombotic treatment on the FIT-based Danish national screening program for CRC. Methods This was a cross-sectional study of all individuals returning a FIT from 2014 until 2016. The effect of antithrombotic treatment on FIT positivity and the positive predictive value (PPV) were assessed using proportions and multivariable Poisson regression. Results Of884 036invitedindividuals,weidentified551 570 participants. A positive FIT was observed in 9052 of 77 007 individuals (11.8 %) receiving antithrombotic treatment compared with 28 387 of 474 587 individuals (6.0%) receiving no treatment. The adjusted relative risk (RR) for a positive FIT was 1.59 (95%CI 1.56-1.63) for any treatment. Nonvitamin K oral anticoagulants (NOACs) were associated with the largest increase in FIT positivity (adjusted RR 2.40, 95 %CI 2.48-2.54). The proportion of CRC detected at colonoscopy was slightly lower among patients on antithrombotic treatment (6.0%, 95%CI 5.5%-6.6%) than among treatment-naïve patients (6.4%, 95%CI 6.1%-6.7%). The PPV for CRC or high risk adenomas was decreased nearly twofold in patients treated with NOAC (adjusted RR 0.58, 95 %CI 0.51-0.66]). Conclusion Antithrombotic treatment was associated with a decreased PPV in FIT-based CRC screening.
AB - Background Screening for colorectal cancer (CRC) using the fecal immunochemical test (FIT) has been widely adopted. The use of antithrombotic treatment is increasing in the Western world. This study aimed to assess the effects of antithrombotic treatment on the FIT-based Danish national screening program for CRC. Methods This was a cross-sectional study of all individuals returning a FIT from 2014 until 2016. The effect of antithrombotic treatment on FIT positivity and the positive predictive value (PPV) were assessed using proportions and multivariable Poisson regression. Results Of884 036invitedindividuals,weidentified551 570 participants. A positive FIT was observed in 9052 of 77 007 individuals (11.8 %) receiving antithrombotic treatment compared with 28 387 of 474 587 individuals (6.0%) receiving no treatment. The adjusted relative risk (RR) for a positive FIT was 1.59 (95%CI 1.56-1.63) for any treatment. Nonvitamin K oral anticoagulants (NOACs) were associated with the largest increase in FIT positivity (adjusted RR 2.40, 95 %CI 2.48-2.54). The proportion of CRC detected at colonoscopy was slightly lower among patients on antithrombotic treatment (6.0%, 95%CI 5.5%-6.6%) than among treatment-naïve patients (6.4%, 95%CI 6.1%-6.7%). The PPV for CRC or high risk adenomas was decreased nearly twofold in patients treated with NOAC (adjusted RR 0.58, 95 %CI 0.51-0.66]). Conclusion Antithrombotic treatment was associated with a decreased PPV in FIT-based CRC screening.
U2 - 10.1055/a-1992-5598
DO - 10.1055/a-1992-5598
M3 - Journal article
C2 - 36702131
AN - SCOPUS:85151873089
VL - 55
SP - 444
EP - 455
JO - Endoscopy
JF - Endoscopy
SN - 0013-726X
IS - 5
ER -
ID: 370568038